Patents by Inventor Paul Strumph

Paul Strumph has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING SUBJECTS HAVING DIABETES WITH CHRONIC KIDNEY DISEASE
    Publication number: 20220387437
    Abstract: The present disclosure is directed to a method of treating prediabetes or type 1 or type 2 diabetes mellitus comprising administering to a subject in need thereof an effective amount of imeglimin, wherein the subject has chronic kidney disease.
    Type: Application
    Filed: January 26, 2022
    Publication date: December 8, 2022
    Inventors: Bill Symonds, Steve Piscitelli, Karen Segal, Ruby Holder, Sophie Bozec, Sébastien Bolze, Pascale Fouqueray, Christophe Arbet-Engels, Julie Dubourg, Paul Strumph, Brandon Dale Swift, Margaret Smith Fletcher
  • Methods of treating subjects having diabetes with chronic kidney disease
    Patent number: 11266652
    Abstract: The present disclosure is directed to a method of treating prediabetes or type 1 or type 2 diabetes mellitus comprising administering to a subject in need thereof an effective amount of imeglimin, wherein the subject has chronic kidney disease.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: March 8, 2022
    Assignee: POXEL SA
    Inventors: Bill Symonds, Steve Piscitelli, Karen Segal, Ruby Holder, Sophie Bozec, Sebastien Bolze, Pascale Fouqueray, Christophe Arbet-Engels, Julie Dubourg, Paul Strumph, Brandon Dale Swift, Margaret Smith Fletcher
  • METHODS OF TREATING SUBJECTS HAVING DIABETES WITH CHRONIC KIDNEY DISEASE
    Publication number: 20200215072
    Abstract: The present disclosure is directed to a method of treating prediabetes or type 1 or type 2 diabetes mellitus comprising administering to a subject in need thereof an effective amount of imeglimin, wherein the subject has chronic kidney disease.
    Type: Application
    Filed: March 9, 2020
    Publication date: July 9, 2020
    Inventors: Bill SYMONDS, Steve PISCITELLI, Karen SEGAL, Ruby HOLDER, Sophie BOZEC, Sebastien BOLZE, Pascale FOUQUERAY, Christophe ARBET-ENGELS, Julie DUBOURG, Paul STRUMPH, Brandon Dale SWIFT, Margaret Smith FLETCHER
  • Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
    Patent number: 8685934
    Abstract: The invention provides methods for treating a patient having type 2 diabetes who has failed on previous regimens of one or more oral and/or injectable anti-diabetic agents, which include the step of administering a therapeutically effective amount of an SGLT2 inhibitor alone or in combination with another anti-diabetic agent and/or other therapeutic agent to such patient. A pharmaceutical composition containing dapagliflozin or dapagliflozin-S-propylene glycol solvate and one or more diabetic agents and/or other therapeutic agents for use in the methods of the invention is also provided.
    Type: Grant
    Filed: May 26, 2010
    Date of Patent: April 1, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Paul Strumph, Stephanie Moran, James List
  • Method for treating cancers having high glucose requirements employing an SGLT2 inhibitor and compositions thereof
    Patent number: 8450286
    Abstract: Methods are provided for treating cancers that have high glucose requirements and that express SGLT2 at levels higher than normal cells, such as metastatic cancers, for example, metastatic lung cancers, employing an SGLT2 inhibitor alone or in combination with a cytotoxic agent and to a composition containing a combination of an SGLT2 inhibitor and a cytotoxic agent.
    Type: Grant
    Filed: March 16, 2009
    Date of Patent: May 28, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mario Maldonado, Paul Strumph
  • Methods for Treating Type 2 Diabetes in Patients Resistant to Previous Treatment with other Anti-Diabetic Drugs Employing an SGLT2 Inhibitor and Compositions Thereof
    Publication number: 20120071403
    Abstract: The invention provides methods for treating a patient having type 2 diabetes who has failed on previous regimens of one or more oral and/or injectable anti-diabetic agents, which include the step of administering a therapeutically effective amount of an SGLT2 inhibitor alone or in combination with another anti-diabetic agent and/or other therapeutic agent to such patient. A pharmaceutical composition containing dapagliflozin or dapagliflozin-S-propylene glycol solvate and one or more diabetic agents and/or other therapeutic agents for use in the methods of the invention is also provided.
    Type: Application
    Filed: May 26, 2010
    Publication date: March 22, 2012
    Applicants: ASTRAZENECA UK LIMITED, BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Paul Strumph, Stephanie Moran, James List
  • METHOD FOR TREATING CANCERS HAVING HIGH GLUCOSE REQUIREMENTS EMPLOYING AN SGLT2 INHIBITOR AND COMPOSITIONS THEREOF
    Publication number: 20110015141
    Abstract: Methods are provided for treating cancers that have high glucose requirements and that express SGLT2 at levels higher than normal cells, such as metastatic cancers, for example, metastatic lung cancers, employing an SGLT2 inhibitor alone or in combination with a cytotoxic agent and to a composition containing a combination of an SGLT2 inhibitor and a cytotoxic agent.
    Type: Application
    Filed: March 16, 2009
    Publication date: January 20, 2011
    Applicants: BRISTOL-MYERS SQUIBB COMPANY, ASTRAZENECA UK LIMITED
    Inventors: Mario Maldonado, Paul Strumph